Condition
Focal Glomerulosclerosis
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Completed3
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00001959Phase 2Completed
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
NCT00302536Not ApplicableWithdrawnPrimary
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
NCT00040508Phase 2CompletedPrimary
Sirolimus for Focal Segmental Glomerulosclerosis
NCT00193648Phase 1CompletedPrimary
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
Showing all 4 trials